Related Experiment Video

Updated: Jul 3, 2026

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

Rosiglitazone promotes atherosclerotic plaque stability in fat-fed ApoE-knockout mice

Mingxue Zhou1, Hao Xu, Lin Pan

  • 1China Academy of Chinese Medical Sciences, Beijing 100700, PR China.

European Journal of Pharmacology
|July 8, 2008
PubMed

Insights

Rosiglitazone stabilizes vulnerable atherosclerotic plaques in mice with type 2 diabetes. This insulin sensitizer improves plaque composition and reduces inflammation, promoting cardiovascular health.

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes is a significant risk factor for cardiovascular disease.
  • Rosiglitazone, an insulin sensitizer, is investigated for cardiovascular disease prevention.
  • The effect of rosiglitazone on atherosclerotic plaque stability remains unclear.

Purpose of the Study:

  • To investigate the impact of rosiglitazone on atherosclerotic plaque stability.
  • To determine if rosiglitazone can stabilize vulnerable plaques in a mouse model.

Main Methods:

  • Utilized fat-fed ApoE-knockout mice, a model for atherosclerosis.
  • Administered rosiglitazone to assess its effects on plaque characteristics.
  • Analyzed plaque composition, fibrous cap thickness, and inflammatory markers.

Main Results:

  • Rosiglitazone demonstrated a plaque-stabilizing effect in the tested mice.
  • Observed modifications in plaque composition, leading to increased stability.
  • Found a decrease in buried fibrous caps and evidence of anti-inflammatory action.

Conclusions:

  • Rosiglitazone can stabilize vulnerable atherosclerotic plaques.
  • Plaque composition modification and anti-inflammatory effects are key mechanisms.
  • These findings suggest a potential therapeutic role for rosiglitazone in cardiovascular disease.

More Related Videos

Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator06:08

Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator

Published on: May 19, 2023

Quantification of Atherosclerosis in Mice06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...